Skip to content

Effects of aerosol inhalation of budesonide and ipratropium bromide on postoperative respiratory function in children with obstructive sleep apnea syndrome (OSAS) : a single-center randomized controlled study

Effects of aerosol inhalation of budesonide and ipratropium bromide on postoperative respiratory function in children with obstructive sleep apnea syndrome (OSAS) : a single-center randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500103372
Enrollment
Unknown
Registered
2025-05-28
Start date
2023-05-20
Completion date
Unknown
Last updated
2025-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive sleep apnea syndrome(OSAS)

Interventions

Experimental group:After mechanical ventilation with tracheal intubation under general anesthesia, the patient was given budesonide + ipratropium bromide atomized inhalation through the respiratory ci
Control group:After mechanical ventilation with tracheal intubation under general anesthesia, the patient was given nebulized saline inhalation through the respiratory circuit

Sponsors

Fujian Children’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 10 Years

Inclusion criteria

Inclusion criteria: 1. Children with obstructive sleep apnea syndrome (OSAS) undergoing tonsillectomy and adenoidectomy under general anesthesia and tracheal intubation for the first time 2. ASA Level I-II, 3. Age 2-10 years old, 4 BMI<35 Kg/cm2. 5. There was no anemia, fever, pulmonary infection, and abnormal blood coagulation before operation.

Exclusion criteria

Exclusion criteria: 1. Craniofacial malformations, such as Down syndrome, mandibular hypoplasia, achondroplasia and generation Metabolic diseases and so on. 2. Nasal anatomical abnormalities, such as deviation of nasal septum, nasal polyps, choanal atresia, etc. 3. History of adenoidectomy or tonsillectomy. 4. Other underlying diseases (congenital heart disease, abnormal liver and kidney function).

Design outcomes

Primary

MeasureTime frame
Hypoxia;Cough;

Secondary

MeasureTime frame
Intubation time;Operation time;Peak Inspiratory Pressure;Pressure Limited Assist Time;

Countries

China

Contacts

Public ContactLu Guolin

Fujian Children's Hospital

drguolinlu@hotmail.com+86 180 5900 7715

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026